Effect of metformin on serum fasting glucose, insulin, HOMA-IR index and serum IGF-I in A) non-diabetic mice (experiment I) and B) diabetic mice (experiment II).

Mice [except saline group] were injected with 1,2-dimethylhydrazine (DMH) weekly for 15 week to induce colon cancer then treated with oxaliplatin and/or metformin (100 or 200 mg/kg) for 4 weeks. HMOA-IR index: homeostasis model assessment index for insulin resistance index, DMH: 1,2-dimethylhydrazine. Mice were treated with the implemented agents for four weeks. HOMA-IR index  =  [fasting glucose (mMol/L) × fasting insulin (µU/ml)]/22.5). Results are expressed as mean ± S.E.M. and analyzed using two-way ANOVA followed by Tukey's post-hoc test.
*P<0.05 compared to saline group.
#P<0.05 compared to DMH group.
$P<0.05 compared to oxaliplatin group, n = 5–6.